Vascular & Endovascular

This channel includes news on non-coronary vascular disease and therapies. These include peripheral artery disease (PAD), abdominal and thoracic aortic aneurysm (AAA and TAA), aortic dissection, pulmonary embolism (PE), critical limb ischemia (CLI), carotid artery and stroke interventions, venous interventions, deep vein thrombosis (DVT), and interventional radiology therapies. The focus on most of these therapies is minimally invasive, catheter-based procedures performed in a cath lab.

RSS icon

ISC: Maintaining life support in ICH patients may lead to more recoveries

The prognosis for intracerebral hemorrhage (ICH) patients may not be as dire as many treating physicians assume, and a significant percentage of such patients may recover an acceptable level of function over time, according to a study comparing ICH patients whose life support was withdrawn to similar patients who remained on life support.

Endo treatment + t-PA not superior to t-PA alone for ischemic stroke

There were similar safety outcomes and no significant differences in functional independence with endovascular therapy after intravenous tissue plasminogen activator (t-PA), as compared with intravenous t-PA alone in patients with moderate-to-severe acute ischemic stroke. The IMS III trial, which was stopped early due to “futility,” was published Feb. 7 ahead of print in the New England Journal of Medicine.

FDA clears new vascular closure system

The FDA has granted Cardiva Medical's premarket approval for the Vascade vascular closure system.

Ramipril improves walking performance in PAD study

Patients with peripheral artery disease (PAD) who received 24-week treatment of ramipril showed significant improvement in pain-free and maximum walking times in a randomized clinical trial. While the results are “particularly notable,” the author of an accompanying editorial cautioned that they may apply to a limited patient population.

Endo treatment for ischemic stroke no better than t-PA

In a randomized trial of patients with acute ischemic stroke, patients receiving endovascular treatment fared no better at 90 days than patients who underwent intravenous thrombolytic therapy. These results were published online ahead of print Feb. 6 in the New England Journal of Medicine.

Long-term rivaroxaban superior to enoxaparin, but adds bleeding risk

A multicenter, randomized, double-blind trial of thromboprophylaxis efficacy has found that patients hospitalized with acute medical illness were less likely to develop deep vein thrombosis or thromboembolism when treated with oral rivaroxaban for 35 days than those who were treated with subcutaneous enoxaparin for 10 days and oral placebo for 35 days. However, the patients treated with rivaroxaban experienced more bleeding events. The MAGELLAN study was published online Feb. 7 in the New England Journal of Medicine.

ABO blood type carries high risk for venous thromboembolism

Danish researchers have determined that ABO blood type, especially when combined with certain genetic mutations, constitutes the most significant risk factor for formation of venous thromboembolism. The findings were published Feb. 4 in the Canadian Medical Association Journal.

ReCor's updated renal denervation system OK’d in Europe

ReCor Medical's updated PARADISE (Percutaneous Renal Denervation) system has received CE Mark in Europe for treating resistant high blood pressure.

Displaying 1425 - 1432 of 1638

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.